Anlon Healthcare share news, announcements and annual reports
NSE: AHCLBSE: 544497Pharmaceuticals & BiotechnologySmall Cap
Anlon Healthcare Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Sep 2025 · Issue price ₹91
Last close ₹25.11up ₹0.64 (2.62%)BSE ₹25.20
Share price at the NSE close on 29 Oct 2026. Previous close ₹24.47.
29 Oct: open ₹24.52, high ₹25.40, low ₹23.94
52-week range of traded prices to 29 Oct 2026
₹10.37Low, 2 Mar 2026₹37.24High, 30 Sep 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 29 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,335 Cr1,681st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 48.03
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed. Price to book: how it is worked out
- 5.19
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 16.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed.
- 0.24
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 41,58,10647.5% delivered
Anlon Healthcare share news and announcements
98 announcements, routine notices left out, newest first. Page 2 of 2.
Apr 2026
Mar 2026
18 Mar · Analysts
9 Mar · Meeting
2 Mar · Board meeting
Feb 2026
13 Feb · Analysts
9 Feb · Results
Jan 2026
Dec 2025
23 Dec · Legal
Exchange has sought clarification from Anlon Healthcare Limited for the quarter ended 30-Jun-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: The response of the Company is awaited.23 Dec · Analysts
19 Dec
8 Dec · Meeting
5 Dec · Board meeting
Nov 2025
25 Nov · Analysts
14 Nov · Analysts
11 Nov · Results
11 Nov · Results
Oct 2025
16 Oct · Board meeting
13 Oct · Board meeting
Sep 2025
27 Sep · Board meeting
24 Sep · Board meeting
23 Sep · Analysts
22 Sep · Analysts
20 Sep · Updates
18 Sep · Legal
The exchange asked on 18 Sep 2025
17 Sep · Analysts